USP9X Inhibits Metastasis in Pulmonary Sarcomatoid Carcinoma by Regulating Epithelial-mesenchymal Transition, Angiogenesis and Immune Infiltration

Overview

Journal Transl Oncol

Specialty Oncology

Date 2024 Jul 4

PMID 38964032

Authors

Qin Feng

Qian Liu

Zi Liu

Jianyu Xu

Yang Yang

Ying Zhu

Guangxian Lu

Guangjuan Xu

Dan Wu

Feng Wang

Biao Liu

Wenjuan Wang

Xinyuan Ding

Affiliations

Soon will be listed here.

Abstract

Background: Pulmonary sarcomatoid carcinoma (PSC) is a highly invasive pulmonary malignancy with an extremely poor prognosis. The results of previous studies suggest that ubiquitin-specific peptidase 9X (USP9X) contributes to the progression of numerous types of cancer. Nevertheless, there is little knowledge about the molecular mechanisms and functions of USP9X in the metastasis of PSC.

Methods: Immunohistochemistry and western blotting were used to detect USP9X expression levels in PSC tissues and cells. Wound healing, transwell, enzyme-linked immunosorbent assay (ELISA), tube formation, and aortic ring assays were used to examine the function and mechanism of USP9X in the metastasis of PSC.

Results: Expression of USP9X was markedly decreased and significantly correlated with metastasis and prognosis of patients with PSC. Then we revealed that USP9X protein levels were negatively associated with the levels of epithelial-mesenchymal transition (EMT) markers and the migration of PSC cells. It was confirmed that USP9X in PSC cells reduced VEGF secretion and inhibited tubule formation of human umbilical vein endothelial cells (HUVEC) in vitro. USP9X was detected to downregulate MMP9. Meanwhile, MMP9 was positively related to EMT, angiogenesis and was negatively related to immune infiltration in the public databases. USP9X was significantly negatively associated with the expression of MMP9, EMT markers, CD31, and positively associated with CD4, and CD8 in PSC tissues.

Conclusion: The present study reveals the vital role of USP9X in regulating EMT, angiogenesis and immune infiltration and inhibiting metastasis of PSC via downregulating MMP9, which provides a new effective therapeutic target for PSC.

References

Wang W, Long L, Yang N, Zhang Q, Ji W, Zhao J . NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro. Acta Pharmacol Sin. 2013; 34(5):681-90. PMC: 4002877. DOI: 10.1038/aps.2013.22. View

Pantazaka E, Vardas V, Roumeliotou A, Kakavogiannis S, Kallergi G . Clinical Relevance of Mesenchymal- and Stem-Associated Phenotypes in Circulating Tumor Cells Isolated from Lung Cancer Patients. Cancers (Basel). 2021; 13(9). PMC: 8124761. DOI: 10.3390/cancers13092158. View

Yang L, Yu S, Yang Y, Zhao Y, Wang F, Chen Y . Muscone derivative ZM-32 inhibits breast tumor angiogenesis by suppressing HuR-mediated VEGF and MMP9 expression. Biomed Pharmacother. 2021; 136:111265. DOI: 10.1016/j.biopha.2021.111265. View

Jiang K, Zhao T, Shen M, Zhang F, Duan S, Lei Z . MiR-940 inhibits TGF-β-induced epithelial-mesenchymal transition and cell invasion by targeting Snail in non-small cell lung cancer. J Cancer. 2019; 10(12):2735-2744. PMC: 6584929. DOI: 10.7150/jca.31800. View

Ding H, Hu H, Tian F, Liang H . A dual immune signature of CD8+ T cells and MMP9 improves the survival of patients with hepatocellular carcinoma. Biosci Rep. 2021; 41(3). PMC: 7969702. DOI: 10.1042/BSR20204219. View

Li Y, Yan B, He S . Advances and challenges in the treatment of lung cancer. Biomed Pharmacother. 2023; 169:115891. DOI: 10.1016/j.biopha.2023.115891. View

Zhao Y, Guo S, Deng J, Shen J, Du F, Wu X . VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment. Int J Biol Sci. 2022; 18(9):3845-3858. PMC: 9254480. DOI: 10.7150/ijbs.70958. View

Li X, Wu D, Liu H, Chen J . Pulmonary sarcomatoid carcinoma: progress, treatment and expectations. Ther Adv Med Oncol. 2020; 12:1758835920950207. PMC: 7450456. DOI: 10.1177/1758835920950207. View

Zhou C, Liang T, Jiang J, Chen J, Chen T, Huang S . MMP9 and STAT1 are biomarkers of the change in immune infiltration after anti-tuberculosis therapy, and the immune status can identify patients with spinal tuberculosis. Int Immunopharmacol. 2023; 116:109588. DOI: 10.1016/j.intimp.2022.109588. View

10.

Maishi N, Hida K . Tumor endothelial cells accelerate tumor metastasis. Cancer Sci. 2017; 108(10):1921-1926. PMC: 5623747. DOI: 10.1111/cas.13336. View

11.

Liu T, Zhao X, Zheng X, Zheng Y, Dong X, Zhao N . The EMT transcription factor, Twist1, as a novel therapeutic target for pulmonary sarcomatoid carcinomas. Int J Oncol. 2020; 56(3):750-760. PMC: 7010216. DOI: 10.3892/ijo.2020.4972. View

12.

Remark R, Becker C, Gomez J, Damotte D, Dieu-Nosjean M, Sautes-Fridman C . The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am J Respir Crit Care Med. 2014; 191(4):377-90. PMC: 5447326. DOI: 10.1164/rccm.201409-1671PP. View

13.

Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean M, Riquet M . Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res. 2013; 19(15):4079-91. DOI: 10.1158/1078-0432.CCR-12-3847. View

14.

Jiang X, Wang J, Deng X, Xiong F, Zhang S, Gong Z . The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res. 2020; 39(1):204. PMC: 7526376. DOI: 10.1186/s13046-020-01709-5. View

15.

Xie S, Wu Z, Qi Y, Wu B, Zhu X . The metastasizing mechanisms of lung cancer: Recent advances and therapeutic challenges. Biomed Pharmacother. 2021; 138:111450. DOI: 10.1016/j.biopha.2021.111450. View

16.

Yuan R, Fan Q, Liang X, Han S, He J, Wang Q . Cucurbitacin B inhibits TGF-β1-induced epithelial-mesenchymal transition (EMT) in NSCLC through regulating ROS and PI3K/Akt/mTOR pathways. Chin Med. 2022; 17(1):24. PMC: 8858510. DOI: 10.1186/s13020-022-00581-z. View

17.

Perez-Mancera P, Rust A, van der Weyden L, Kristiansen G, Li A, Sarver A . The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature. 2012; 486(7402):266-70. PMC: 3376394. DOI: 10.1038/nature11114. View

18.

Sullivan S, Tosetto M, Kevans D, Coss A, Wang L, ODonoghue D . Localization of nuclear cathepsin L and its association with disease progression and poor outcome in colorectal cancer. Int J Cancer. 2009; 125(1):54-61. DOI: 10.1002/ijc.24275. View

19.

Huang Y, Fang J, Lu W, Wang Z, Wang Q, Hou Y . A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling. Cell Chem Biol. 2019; 26(8):1143-1158.e6. PMC: 6697584. DOI: 10.1016/j.chembiol.2019.05.004. View

20.

Han S, Wang R, Zhang Y, Li X, Gan Y, Gao F . The role of ubiquitination and deubiquitination in tumor invasion and metastasis. Int J Biol Sci. 2022; 18(6):2292-2303. PMC: 8990454. DOI: 10.7150/ijbs.69411. View